Cancer nanomedicines: oversold or underappreciated? (Q33602272)

28 July 2017

0 references

Cancer nanomedicines: oversold or underappreciated? (English)

1 reference

28 July 2017

1 reference

Roy van der Meel

1

0 references

Twan Lammers

object named as

Twan Lammers

series ordinal

2

0 references

Wim Hennink

series ordinal

3

object named as

Wim E Hennink

1 reference

PubMed ID

27852113

28 July 2017

language of work or name

English

0 references

publication date

17 November 2016

1 reference

Expert Opinion on Drug Delivery

28 July 2017

1 reference

28 July 2017

14

1 reference

28 July 2017

1

1 reference

28 July 2017

1-5

1 reference

Cancer nanomedicine: Is targeting our target?

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Mechanism of hard-nanomaterial clearance by the liver.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Antibody-drug conjugates for cancer therapy.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Extracellular vesicles as drug delivery systems: lessons from the liposome field

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Remote loading of preencapsulated drugs into stealth liposomes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Analysis on the current status of targeted drug delivery to tumors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5404718

Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains.

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F17425247.2017.1262346

Lessons in simplicity that should shape the future of drug delivery.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F17425247.2017.1262346

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27852113

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/17425247.2017.1262346

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

PubMed ID

27852113